In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Neurocrine (NBIX), with a price target of $115.00. The company’s shares closed last Monday at $103.10.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 7.7% and a 51.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $126.13 average price target, representing a 24.7% upside. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $126.00 price target.
See today’s analyst top recommended stocks >>
Neurocrine’s market cap is currently $9.49B and has a P/E ratio of 610.42. The company has a Price to Book ratio of 16.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
